Grünenthal donates €400,000 and supplies pain medication to Ukraine

Madeira Public Health Service SESARAM EPERAM collaborates with the EU | mifuturonorcal

Aachen, Germany, March 7, 2022 – Grünenthal, a science-led international pharmaceutical company, announced that it has donated €400,000 to the Red Cross to support humanitarian aid in Ukraine and Eastern Europe. Furthermore, Grünenthal cooperates with Action partner and RWTH Aachen University Hospital to supply urgent pain medication to the region. The first shipment of medicines will leave Aachen this week.

“We are shocked and saddened by the attack on Ukraine. Our full solidarity goes to the Ukrainian people and to all those affected by them, regardless of where they come from. Grünenthal will help ensure urgent medical care,” said Gabriel Baertschi, CEO of Grünenthal.

About Grünenthal
Grünenthal is a global leader in the management of pain and related diseases. As a science-based privately held pharmaceutical company, we have a long track record of bringing innovative treatments and cutting-edge technologies to patients around the world. Our purpose is to change lives for the better and innovation is our passion. We are focusing all of our activities and efforts on working toward our vision of a pain-free world.

Grünenthal is headquartered in Aachen, Germany, and has subsidiaries in 29 countries in Europe, Latin America and the United States. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved a turnover of 1.3 billion euros.

More information:

Follow us on:
LinkedIn: Grünenthal Group
Instagram: grunenthal

For more information, please contact:
Fabia Kehren, head of external communication and editorial management
Phone: +49 241 569-3269
Grünenthal GmbH, 52099 Aachen, Germany